Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
about
Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphomaProfile and outcome of childhood mycosis fungoides in Singapore.Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosisDiverse cutaneous manifestations associated with a single disease.Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaManagement of the primary cutaneous lymphomas.Treatment planning in cutaneous T-cell lymphoma.Management with topical nitrogen mustard in mycosis fungoides.Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma.Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma.Elucidating the role of interleukin-17F in cutaneous T-cell lymphomaPhase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.Clinical results of the total skin electron irradiation of the mycosis fungoides in adults. Conventional fractionation and low dose schemes.UVB in the management of early stage mycosis fungoides.Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy.Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy.Innovative Approaches to Radiation Treatment for Mycosis Fungoides in the Setting of Collagen Vascular DiseaseLong-term control of mycosis fungoides of the hands with topical bexarotene.Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas.18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.Development of mycosis fungoides after bone marrow transplantation for chronic myeloid leukaemia: transmission from an allogeneic donorNeoplasms
P2860
Q33783663-E3FC9967-E7E3-485F-B7E0-AC32DCBC780FQ34086289-3232D831-61A3-4EDC-AED9-F4B5D9C3D722Q34100988-20E9EBB6-3FB1-4FF7-B6E6-F6B83AF0CC80Q34116799-EE11E596-CAA7-4F59-843F-4C0FC3789A13Q35186682-12C6C8C9-CD1A-4DC9-B615-8185499F4BDAQ35583232-0C19B840-536F-4546-8456-0D6D364983A7Q35612011-B1BDBB24-0DA9-4D30-9531-642419F89B9EQ35612016-90399FB9-BB44-419D-B8AA-FA8DD700A5A7Q36370759-050F39D0-0D1A-4286-A094-5931FCB8CC1AQ36459144-A25E6064-7B2A-47B6-BB77-33514648C0AFQ36930962-D863A870-570D-4E84-A216-2C27E43B135CQ37216178-5E714DD3-4145-4F42-9022-38CA3B04E051Q37323004-AF01CF08-165D-40A5-A00C-B39E841BDCEAQ37379370-3428DF4D-A39F-4442-B5EB-4B1382833E18Q38220827-E6304F9B-9497-4CA0-90DE-2E0EC103F3E5Q40326881-4AB76A86-07B9-46CC-9CAF-281651F163EBQ40607594-AC4565E5-DDA9-46C2-A8A9-D577D26F2F15Q42463819-8EA026B7-161B-42AE-825D-9824D8AB7C9BQ42582617-47582E33-CD84-4F82-AB9C-183F9534596AQ44373713-C1CDFE5C-374E-405E-8443-0D3A2EF0EC2FQ46006814-6FCE806F-8CB4-4742-A14B-8A396878D50FQ46572255-C285AA55-F1AC-4A56-B4B2-19538AE25B85Q47654977-35C59F80-2E4B-482B-94AA-657C6819F13BQ52889526-B659E773-2302-483D-855B-63B2495604DCQ53526491-8DC00F58-E9A6-4A96-AA93-3223778BE418Q53635286-B5A67EAC-45BE-42C4-8920-026304CD647DQ56112331-AEE944FB-E7FF-4C76-BDB9-9157741333E5Q56828372-BD205C1C-95A6-4FD6-A074-E04D4D5DA35D
P2860
Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Clinical characteristics and l ...... plaque (T2) mycosis fungoides.
@en
Clinical characteristics and l ...... eneralized patch and/or plaque
@nl
type
label
Clinical characteristics and l ...... plaque (T2) mycosis fungoides.
@en
Clinical characteristics and l ...... eneralized patch and/or plaque
@nl
prefLabel
Clinical characteristics and l ...... plaque (T2) mycosis fungoides.
@en
Clinical characteristics and l ...... eneralized patch and/or plaque
@nl
P2093
P1433
P1476
Clinical characteristics and l ...... plaque (T2) mycosis fungoides.
@en
P2093
P356
10.1001/ARCHDERM.135.1.26
P577
1999-01-01T00:00:00Z